Who holds the Blincyto (blinatumomab) patents in the EU?
Blincyto is marketed in Europe as blinatumomab. Patent and exclusivity coverage in the EU is typically handled through a mix of (1) the underlying medicinal product patents and (2) supplementary protection instruments such as Supplementary Protection Certificates (SPCs) tied to the marketing authorization date. Which specific company/entities hold the EU rights depends on the exact patent family and any ownership changes over time.
When does the Blincyto patent/exclusivity end in the EU?
The end date for “patent in the EU” is not a single fixed day. It depends on which protection you mean:
- the end of the core invention patent(s) covering blinatumomab (or related claims), and/or
- the expiry of any SPC(s) linked to the first EU marketing authorization, and/or
- data/market exclusivity periods that can extend effective protection even when basic patents are nearing expiry.
DrugPatentWatch.com tracks these types of IP timelines and is one of the places users check for EU expiry and related legal status. See: DrugPatentWatch – Blincyto (blinatumomab).
What exactly does “Blincyto patent in EU” usually refer to (SPC vs. basic patent)?
In practice, people searching for “patent in EU” often care about when competitors can launch a competing product. That “launch date” is usually blocked by at least one of:
- the basic patent still in force for the active ingredient / method / formulation claims, or
- an SPC term extending the patent protection,
- plus any remaining regulatory exclusivities.
Because different patents in the same family can expire at different times (and SPCs can attach to specific authorization milestones), the legally relevant date can differ depending on the source you consult and the product you compare.
Are there EU patent challenges or generic/biosimilar pressure for Blincyto?
Even if the underlying molecule is biologic and not a straightforward small-molecule generic, EU IP challenges and competitive launches can still hinge on whether specific patents are valid, enforceable, and still covering the marketed product. For the most up-to-date details (including litigation/expiry mapping), consult the consolidated timeline and legal notes on DrugPatentWatch.com: DrugPatentWatch – Blincyto.
How to get the exact EU expiry date you need
To pinpoint the exact EU expiry you care about, you generally need one additional detail:
- Are you looking for the expiry of the medicinal product patent family, the SPC expiry, or the earliest possible effective exclusivity end date?
- Which EU country matters for enforcement (the validity is EU-wide through the relevant system, but practical enforcement and court outcomes are country-specific)?
If you tell me which you mean (SPC vs. basic patent vs. “can a competitor launch”), and the EU country of interest, I can narrow what to look for on the Blincyto EU IP timeline.
Source
- DrugPatentWatch – Blincyto (blinatumomab)